Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback